US Patent

US10086047 — Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Formulation · Assigned to Novo Nordisk AS · Expires 2031-12-16 · 6y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid compositions that combine a GLP-1 agonist with a specific type of salt, used in medicine.

USPTO Abstract

The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
US10086047
Jurisdiction
US
Classification
Formulation
Expires
2031-12-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.